Monoclonal antibodies can provide efficacious therapy for COVID-19 treatment, but rapid mutation of the virus frequently leads to viral escape. Immunome is developing a SARS-CoV-2 three-antibody cocktail with broad neutralization potency and a goal of retaining efficacy even as the virus mutates. Immunome needed to test their antibody cocktail against a large panel of viral variants of concern.
Immunome used Integral Molecular’s Reporter Virus Particles (RVPs) as a critical reagent to test their SARS-CoV-2 antibody cocktail against a broad panel of SARS-CoV-2 variants in pseudovirus neutralization assays. RVPs display the SARS-CoV-2 spike protein pseudotyped onto non-replicative lentiviral particles and provide a rapid and safe (BSL-2) alternative to using live virus for assaying the neutralizing effects of SARS-CoV-2 antibodies.
Integral Molecular’s catalog of 70+ variant SARS-CoV-2 RVPs includes all variants of concern and variants of interest. Our molecular biology team maintains close surveillance over emerging viral variants to quickly produce new RVPs.
Immunome used SARS-CoV-2 RVPs to show that their antibody cocktail neutralized all variants tested including Alpha, Gamma and Delta and provided comparable results to other methods including live virus assays. The availability of a comprehensive panel of SARS-CoV-2 RVPs enabled Immunome to meet FDA guidance requiring developers to routinely monitor genomic databases for emerging SARS-CoV-2 variants and report the neutralizing activity of their antibody against circulating variants. In accordance with FDA guidance, Immunome also characterized the epitopes bound by their antibody cocktail using Integral Molecular’s high-resolution Shotgun Mutagenesis epitope mapping.
Immunome’s three-antibody cocktail IMM-BCP-01 is presently in a Phase 1 clinical trial (NCT05429021) to test safety and tolerability in patients with mild to moderate COVID-19.